Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Concise Review
  • Published:

Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways

Leukemia volume 26, pages 1174–1179 (2012)Cite this article

Subjects

Abstract

CK2 is a multitask kinase whose role is essential for a countless number of cellular processes, many of which are critical for blood cell development. A prevailing task for this kinase rests on counteracting programmed cell death triggered by multiple stimuli. CK2 is overexpressed in many solid tumors and in vivo mouse models have proven its tumorigenic potential. Recent data have suggested that CK2 may also have a significant role in the pathogenesis of hematopoietic tumors, such as multiple myeloma, chronic lymphocytic leukemia, acute myelogenous leukemia, acute lymphoblastic leukemia and chronic myeloproliferative neoplasms. CK2 regulates hematopoiesis-associated signaling pathways and seems to reinforce biochemical cascades indispensable for tumor growth, proliferation and resistance to conventional and novel cytotoxic agents. Although its activity is multifold, recent evidence supports the rationale of CK2 inhibition as a therapeutic strategy in solid and hematological tumors and phase-I clinical trials are in progress to test the efficacy of this innovative therapeutic approach. In this review, we will summarize the data supporting CK2 as an oncogenic kinase in blood tumors and we will describe some critical signaling pathways, whose regulation by this protein kinase may be implicated in tumorigenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. St-Denis NA, Litchfield DW . Protein kinase CK2 in health and disease: from birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 2009; 66: 1817–1829.

    Article  CAS  PubMed  Google Scholar 

  2. Litchfield DW . Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369 (Pt 1): 1–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Meggio F, Pinna LA . One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003; 17: 349–368.

    Article  CAS  PubMed  Google Scholar 

  4. Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB et al. Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 2003; 23: 908–915.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Seldin DC, Lou DY, Toselli P, Landesman-Bollag E, Dominguez I . Gene targeting of CK2 catalytic subunits. Mol Cell Biochem 2008; 316: 141–147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Xu X, Toselli PA, Russell LD, Seldin DC . Globozoospermia in mice lacking the casein kinase II alpha’ catalytic subunit. Nat Genet 1999; 23: 118–121.

    Article  CAS  PubMed  Google Scholar 

  7. Ruzzene M, Pinna LA . Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2010; 1804: 499–504.

    Article  CAS  PubMed  Google Scholar 

  8. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K . Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009; 66: 1858–1867.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gyenis L, Litchfield DW . The emerging CK2 interactome: insights into the regulation and functions of CK2. Mol Cell Biochem 2008; 316: 5–14.

    Article  CAS  PubMed  Google Scholar 

  10. Filhol O, Cochet C . Protein kinase CK2 in health and disease: cellular functions of protein kinase CK2: a dynamic affair. Cell Mol Life Sci 2009; 66: 1830–1839.

    Article  CAS  PubMed  Google Scholar 

  11. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K . Protein kinase CK2 signal in neoplasia. Histol Histopathol 2001; 16: 573–582.

    CAS  PubMed  Google Scholar 

  12. McNeill H, Woodgett JR . When pathways collide: collaboration and connivance among signalling proteins in development. Nat Rev Mol Cell Biol 2010; 11: 404–413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Staal FJ, Luis TC . Wnt signaling in hematopoiesis: crucial factors for self-renewal, proliferation, and cell fate decisions. J Cell Biochem 2010; 109: 844–849.

    CAS  PubMed  Google Scholar 

  14. Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I . CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem 2005; 274: 63–67.

    Article  CAS  PubMed  Google Scholar 

  15. Song DH, Sussman DJ, Seldin DC . Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem 2000; 275: 23790–23797.

    Article  CAS  PubMed  Google Scholar 

  16. Wang S, Jones KA . CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr Biol 2006; 16: 2239–2244.

    Article  CAS  PubMed  Google Scholar 

  17. Ponce DP, Maturana JL, Cabello P, Yefi R, Niechi I, Silva E et al. Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent up-regulation of beta-catenin transcriptional activity. J Cell Physiol 2011; 226: 1953–1959.

    Article  CAS  PubMed  Google Scholar 

  18. Ponce DP, Yefi R, Cabello P, Maturana JL, Niechi I, Silva E et al. CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem 2011; 356: 127–132.

    Article  CAS  PubMed  Google Scholar 

  19. Jiang J, Hui CC . Hedgehog signaling in development and cancer. Dev Cell 2008; 15: 801–812.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mar BG, Amakye D, Aifantis I, Buonamici S . The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Leukemia 2011; 25: 1665–1673.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jia H, Liu Y, Xia R, Tong C, Yue T, Jiang J et al. Casein kinase 2 promotes Hedgehog signaling by regulating both smoothened and Cubitus interruptus. J Biol Chem 2010; 285: 37218–37226.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jin Z, Mei W, Strack S, Jia J, Yang J . The antagonistic action of B56-containing protein phosphatase 2As and casein kinase 2 controls the phosphorylation and Gli turnover function of Daz interacting protein 1. J Biol Chem 2011; 286: 36171–36179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Salmena L, Carracedo A, Pandolfi PP . Tenets of PTEN tumor suppression. Cell 2008; 133: 403–414.

    Article  CAS  PubMed  Google Scholar 

  24. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441: 518–522.

    Article  CAS  PubMed  Google Scholar 

  25. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475–482.

    Article  CAS  PubMed  Google Scholar 

  26. Torres J, Pulido R . The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001; 276: 993–998.

    Article  CAS  PubMed  Google Scholar 

  27. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T . Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 2005; 280: 35195–35202.

    Article  CAS  PubMed  Google Scholar 

  28. Barata JT . The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 2010; 51: 37–49.

    Article  PubMed  Google Scholar 

  29. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 2005; 12: 668–677.

    Article  CAS  PubMed  Google Scholar 

  30. Di Maira G, Brustolon F, Pinna LA, Ruzzene M . Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci 2009; 66: 3363–3373.

    Article  PubMed  Google Scholar 

  31. Cures A, House C, Kanei-Ishii C, Kemp B, Ramsay RG . Constitutive c-Myb amino-terminal phosphorylation and DNA binding activity uncoupled during entry and passage through the cell cycle. Oncogene 2001; 20: 1784–1792.

    Article  CAS  PubMed  Google Scholar 

  32. Lodie TA, Reiner M, Coniglio S, Viglianti G, Fenton MJ . Both PU.1 and nuclear factor-kappa B mediate lipopolysaccharide- induced HIV-1 long terminal repeat transcription in macrophages. J Immunol 1998; 161: 268–276.

    CAS  PubMed  Google Scholar 

  33. Tan NY, Khachigian LM . Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 2009; 29: 2483–2488.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Scaglioni PP, Yung TM, Choi S, Baldini C, Konstantinidou G, Pandolfi PP . CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol Cell Biochem 2008; 316: 149–154.

    Article  CAS  PubMed  Google Scholar 

  35. Kelliher MA, Seldin DC, Leder P . Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J 1996; 15: 5160–5166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Shirai A, Klinman DM . The genetic basis of autoimmune disease in MRL-lpr/lpr mice. Int Rev Immunol 1994; 11: 179–192.

    Article  CAS  PubMed  Google Scholar 

  37. Rifkin IR, Channavajhala PL, Kiefer HL, Carmack AJ, Landesman-Bollag E, Beaudette BC et al. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha. J Immunol 1998; 161: 5164–5170.

    CAS  PubMed  Google Scholar 

  38. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC . p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 1998; 16: 2965–2974.

    Article  CAS  PubMed  Google Scholar 

  39. Channavajhala P, Seldin DC . Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002; 21: 5280–5288.

    Article  CAS  PubMed  Google Scholar 

  40. Mishra S, Reichert A, Cunnick J, Senadheera D, Hemmeryckx B, Heisterkamp N et al. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003; 22: 8255–8262.

    Article  CAS  PubMed  Google Scholar 

  41. Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J et al. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 2007; 21: 178–180.

    Article  CAS  PubMed  Google Scholar 

  42. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762–3774.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Silva A, Jotta PY, Silveira AB, Ribeiro D, Brandalise SR, Yunes JA et al. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. Haematologica 2009; 95: 674–678.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010; 116: 2513–2521.

    Article  CAS  PubMed  Google Scholar 

  45. Martins LR, Lucio P, Silva MC, Anderes KL, Gameiro P, Silva MG et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116: 2724–2731.

    Article  CAS  PubMed  Google Scholar 

  46. Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O’Brien SE et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010; 70: 10288–10298.

    Article  CAS  PubMed  Google Scholar 

  47. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698–1707.

    Article  CAS  PubMed  Google Scholar 

  48. Ge F, Xiao CL, Bi LJ, Tao SC, Xiong S, Yin XF et al. Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells. PLoS One 2010; 5: 1–11.

    Google Scholar 

  49. Phan-Dinh-Tuy F, Henry J, Boucheix C, Perrot JY, Rosenfeld C, Kahn A . Protein kinases in human leukemic cells. Am J Hematol 1985; 19: 209–218.

    Article  CAS  PubMed  Google Scholar 

  50. Roig J, Krehan A, Colomer D, Pyerin W, Itarte E, Plana M . Multiple forms of protein kinase CK2 present in leukemic cells: in vitro study of its origin by proteolysis. Mol Cell Biochem 1999; 191: 229–234.

    Article  CAS  PubMed  Google Scholar 

  51. Heriche JK, Chambaz EM . Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases. Oncogene 1998; 17: 13–18.

    Article  CAS  PubMed  Google Scholar 

  52. Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007; 13: 1019–1028.

    Article  CAS  PubMed  Google Scholar 

  53. Cheong JW, Min YH, Eom JI, Kim SJ, Jeung HK, Kim JS . Inhibition of CK2{alpha} and PI3K/Akt synergistically induces apoptosis of CD34+CD38- leukaemia cells while spari. Anticancer Res 2010; 30: 4625–4634.

    CAS  PubMed  Google Scholar 

  54. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, Tefferi A et al. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 2011; 118: 156–166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ljubimov AV, Caballero S, Aoki AM, Pinna LA, Grant MB, Castellon R . Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci 2004; 45: 4583–4591.

    Article  PubMed  Google Scholar 

  56. Kramerov AA, Saghizadeh M, Pan H, Kabosova A, Montenarh M, Ahmed K et al. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol 2006; 168: 1722–1736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Ruzzene M, Pinna LA . Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2009; 1804: 499–504.

    Article  PubMed  Google Scholar 

  58. Solimini NL, Luo J, Elledge SJ . Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007; 130: 986–988.

    Article  CAS  PubMed  Google Scholar 

  59. Di Maira G, Brustolon F, Bertacchini J, Tosoni K, Marmiroli S, Pinna LA et al. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 2007; 26: 6915–6926.

    Article  CAS  PubMed  Google Scholar 

  60. Ruzzene M, Tosoni K, Zanin S, Cesaro L, Pinna LA . Protein kinase CK2 accumulation in ‘oncophilic’ cells: causes and effects. Mol Cell Biochem 2011; 356: 5–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Italian Ministry of University and Scientific Research (MIUR) grant no. RBFR086EW9 (FIRB - Futuro in Ricerca) to FP and by a grant from Associazione Italiana Ricerca sul Cancro (AIRC) to GS.

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Branch, University of Padua School of Medicine, Padua, Italy

    F Piazza, S Manni, C Gurrieri & G Semenzato

  2. Department of Biological Chemistry, University of Padua, Padua, Italy

    M Ruzzene & L A Pinna

  3. Venetian Institute of Molecular Medicine, Hematological Malignancies Unit, Padua, Italy

    F Piazza, S Manni, M Ruzzene, L A Pinna, C Gurrieri & G Semenzato

Authors
  1. F Piazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Manni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Ruzzene
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L A Pinna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Gurrieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Semenzato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Piazza.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piazza, F., Manni, S., Ruzzene, M. et al. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 26, 1174–1179 (2012). https://doi.org/10.1038/leu.2011.385

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.385

Keywords

This article is cited by

Search

Advanced search

Quick links